Pharmacological treatment for prevention of restenosis

Expert Opinion on Emerging Drugs

Volumn 6, Issue 2, 2001, Pages 281-302

  Linde, Jacek ^a   Strauss, Bradley H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cell proliferation; Extracellular matrix PTCA; Restenosis; Smooth muscle cells; Stent

Indexed keywords

ABCIXIMAB; ALCOHOL; ANGIOPEPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HALOFUGINONE; HEPARIN; HYALURONIC ACID; INTEGRIN; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE; OCTREOTIDE; PACLITAXEL; PEMIROLAST; PROBUCOL; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; STEROID; SULINDAC; SURAMIN; TIROFIBAN; TRANILAST; TRAPIDIL; TROGLITAZONE; VITRONECTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; BLOOD CLOTTING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; EXTRACELLULAR MATRIX; GENE THERAPY; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0035493820     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.2.281     Document Type: Review

References (255)

1. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome
2. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularisation Investigation (BARI)
3. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease
4. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation
5. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement
6. Genetic risk factors and restenosis after percutaneous coronary interventions
7. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: A major risk factor and a marker of risk for coronary stent restenosis
8. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
9. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis
10. Comparison of outcome after stenting for de novo versus restenotic narrowings in native coronary arteries
11. Vessel size and long-term outcome after coronary stent placement
12. Influence of lesion length on restenosis after coronary stent placement
13. Clinical and angiographic outcome after stent placement for chronic coronary occlusion
14. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts
15. Coronary angioplasty after coronary bypass surgery: Initial results and late outcome in 422 patients
16. Predictive factors of restenosis after coronary stent placement
17. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty
18. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study
19. Arterial remodelling after coronary angioplasty: A serial intravascular ultrasound study
20. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy
21. Remodelling and restenosis: Observations from Serial Intravascular Ultrasound Studies
22. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
23. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
24. Randomised comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): A four-year follow-up
25. In-hospital and one-year economic ontcomes after coronary stenting or balloon angioplasty. Results from a randomised clinical trial
26. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts
27. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty
28. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin
29. European high-activity (32)P radioactive stent experience
30. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents
31. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting
32. Achieving optimal results with standard balloon angioplasty
33. Irradiation and postangioplasty restenosis: A recent overview
34. Effect of intracoronary gamma-radiation therapy on in-stent restenosis: An intravascular ultrasound analysis from the gamma-1 study
35. Prevention of coronary restenosis: The evolving evidence base for radiation therapy
36. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis
37. Vascular brachytherapy: Update on clinical trials
38. Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomised clinical trial
39. Radiation for restenosis: Watchful waiting
40. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT)
41. Late arterial responses (6 and 12 months) after (32)P beta-emitting stent placement: Sustained intimal suppression with incomplete healing
42. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study
43. I like the candy, I hate the wrapper: The (32)P radioactive stent
44. Coronary in-stent restenosis - Predictors, treatment and prevention
45. Restenosis: A challenge for pharmacology
46. Platelets and restenosis
47. Prevention of restenosis after percutaneous coronary interventions: The medical approach
48. Prevention of coronary restenosis
49. Pharmacological approaches to the prevention of restenosis after coronary angioplasty
50. Restenosis, the Achilles' heel of coronary angioplasty
51. Prevention of restenosis after coronary angioplasty: Towards a molecular approach?
52. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part I)
53. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II)
54. Toward new therapeutic strategies against neointimal formation in restenosis
55. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures
56. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention
57. Anti-restenosis trials
58. Novel approaches for the prevention of restenosis
59. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
60. Update on pharmacology for restenosis
61. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
62. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
63. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting
64. Unexpected mortality reduction with abciximab for in-stent restenosis
65. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularisation in patients with diabetes mellitus: Results of the EPISTENT trial
66. Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells
67. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 fab (abciximab): A possible mechanism for influencing restenosis
68. Six-month angiographic and clinical follow-up of patients prospectively randomised to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomised efficacy study of tirofiban for outcomes and restenosis
69. Eptifibatide in percutaneous coronary intervention: The ESPRIT trial results
70. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
71. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
72. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
73. Decreased neointimal formation in Mac-1 (-/-) mice reveals a role for inflammation in vascular repair after angioplasty
74. Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty
75. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomised trials
76. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21
77. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery
78. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
79. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
80. Impact of cilostazol on intimal proliferation after directional coronary atherectomy
81. A randomised trial of aspirin versus cilostazol therapy after successful coronary stent implantation
82. A randomised comparison of cilostazol vs. ticlopidine after coronary stent implantation
83. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation
84. Impact of cilostazol on restenosis after AVE-GFX stent implantation
85. Effect of cilostazol on long-term clinical outcome after Palmaz-Schatz stent implantation
86. Effects of cilostazol on angiographic restenosis after coronary stent placement
87. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation
88. Heparin rapidly selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells
89. Heparin inhibits human coronary artery smooth muscle cell migration
90. Percutaneous delivery of a heparin-impregnated collagen stent-graft in a porcine model of atherosclerotic disease
91. Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery
92. The role of local low molecular weight heparin delivery in prevention of restenosis following coronary intervention
93. Effect of nadroparin, a low-molecular-weight heparin, on clinical andangiographic restenosis after coronary balloon angioplasty: The FACT study
94. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: Results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study
95. Heparin infusion prior to stenting (HIPS) trial: Final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia
96. Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study)
97. Antiproliferative effects of trapidil in vascular smooth muscle cells are associated by inhibition of MAPK and P34(cdc2) activity
98. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A
99. Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model
100. Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery
101. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty
102. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomised, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica
103. A randomised comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation
104. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy
105. Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: Potential drug for prevention of restenosis by local drug delivery
106. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin
107. Inhibitory mechanisms by which suramin may attenuate neointimal formation after balloon angioplasty
108. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo
109. A Phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response
110. Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro
111. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034
112. Early inhibition of myointimal proliferation by angiopeptin after balloon catheter injury in the rabbit
113. Angiopeptin inhibition of myointimal hyperplasia after balloon angioplasty of large arteries in hypercholesterolaemic rabbits
114. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries
115. Single-dose intramuscular administration of sustained-release angiopeptin reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model
116. Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model
117. Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries
118. Randomised double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty
119. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis
120. Verringerung der restenoserate nach angioplastic durch ein somatostatinanalogon
121. Local delivery of platelet-derived growth factor receptor-specific tyrphostininhibits neointimal formation in rats
122. Protein tyrosine kinase inhibitors as novel therapeutic agents
123. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1
124. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21 (waf1/cip1/sdi1) and p53
125. Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart
126. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats
127. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors
128. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells
129. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat
130. Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery
131. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT)
132. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial
133. Effects of an antiallergic drug, pemirolast potassium on tyrosinephosphorylation and map kinase activation in antigen-stimulated rat basophilicleukemia (RBL-2H3) cells
134. 2+ mobilization in antigen-stimulated ratbasophilic leukemia (RBL-2H3) cells
135. Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: Serial coronary angiography and intravascular ultrasound studies
136. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty
137. Mechanism of the combination immunosuppressive effects of rapamycin with eirhercyclosporine or tacrolimus
138. XETOR signaling regulates microtubule structure and function
139. Rapamycin inhibits vascular smooth muscle cell migration
140. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
141. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
142. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries a quantitative coronary angiography and three-dimensional intravascular ultrasound study
143. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
144. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat
145. Paclitaxel: A chemotherapeutic agent for prevention of restenosis? Experimental suldies in vitro and in vivo
146. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months
147. Paclitaxel applied directly to stents inhibits neointimal growth without thrombotic complications in a porcine coronary artery model of restenosis
148. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: Effects on neointimal hyperplasia and vascular remodelling
149. Use of nitric-oxide-eluting polymer-coated coronary steals for prevention of restenosis in pigs
150. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem
151. Halofuginone: A novel antifibrotic therapy
152. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone
153. Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro
154. Halofuginone an inhibitor of collagen synthesis, reduces neointimal hyperplasia in a porcine coronary stent model
155. Ethanol inhibits mitogen activated protein kinase activity and growth of vascular smooth muscle cells in vitro
156. Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model
157. Local delivery of ethanol inhibits intimal hyperplasia in pig coronary arteries after balloon injury
158. Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury
159. Initial human experience with intramural ethyl alcohol treatment of in-stent restenosis: The Beaumont Alcoholc Restenosis Study (BARS)
160. Safety study of coronary intramural ethyl alcohol delivery in reducing intimal hyperplasia after successful coronary stenting
161. Effect of HMG-CoA rcductase inhihitors on extracellular matrix expression in human vascular smooth muscle cells
162. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures
163. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
164. Direct vascular effects of HMG-CoA reductase inhibitors
165. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to fas-ligand and cytokine-induced cell death
166. Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration
167. Prevention of restenosis by lovastatin after successful coronary angioplasty
168. Lack of effect of lovastatin on restenosis after coronary angioplasty
169. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty
170. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. Prevention of restenosis by Elisor after transluminal coronary angioplasty
171. A randomised placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
172. Effect of statin therapy on restenosis after coronary stent implantation
173. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
174. Stimulation of platelet-derived growth factor-induced DNA synthesis by angiotensin II in rabbit vascular smooth muscle cells
175. Role of the lipoxygenase pathway in angiotensin Il-induced vascular smooth muscle cell hypertrophy
176. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
177. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall
178. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells
179. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model
180. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model
181. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs
182. Local administration of ramiprilat is less effective than oral ramipril in preventing restenosis after balloon angioplasty in an animal model
183. Benazepril on tissue angiotensin-converting enzyme and cellular proliferation in restenosis after experimental angioplasty
184. Suppression of the vascular response to injury: The role of angiotensin-converting enzyme inhibitors
185. Enalapril in the prevention of restenosis following intracoronary intervention in a swine model
186. Effect of angiotensin converting enzyme inhibition on the incidence of restenosis after percutaneous transluminal coronary angioplasty
187. Enalapril for prevention of restenosis after coronary angioplasty
188. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomised, double-blind placebo-controlled trial
189. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril
190. Valsartan for prevention of restenosis after stenting of type b2/c lesions: The val-prest trial
191. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound
192. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial
193. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro
194. 17 Beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: Similar effects in cells from postmenopausal females and in males
195. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries
196. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model
197. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation
198. A randomised trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty
199. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty
200. Prospective randomised trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation
201. Persistent high restenosis after local intrawall delivery of long-acting steroids before coronary stent implantation
202. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice
203. Oxidative stress as a signaling mechanism of the vascular response to injury: The redox hypothesis of restenosis
204. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells
205. Effect of probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: Possible role of PDGF
206. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit
207. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis
208. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial
209. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty
210. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty
211. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
212. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART])
213. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty
214. Effects of probucol on vascular remodelling after coronary angioplasty
215. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis
216. Probucol promotes reendotheliazation after balloon injury
217. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
218. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
219. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
220. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
221. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat
222. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases
223. Oral matrix metalloproteinase inhibition and arterial remodelling after balloon dilation: An intravascular ultrasound study in the pig
224. Matrix metalloproteinase inhibitor GM6001 selectively reduce intimal hyperplasia and intimal collagen content in stented but not balloon treated arteries
225. The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2, and phenotypic modification of arterial smooth muscle cells in vitro
226. Distribution of hyaluronan during extracellular matrix remodelling in human restenotic arteries and balloon-injured rat carotid arteries
227. Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: Role of CD44 and implications for constrictive remodelling
228. Role of hyaluronic acid in the arterial response to angioplasty
229. Integrins: Versatility, modulation, and signaling in cell adhesion
230. Integrins
231. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA
232. Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration
233. Function and regulation of the beta 3 integrins in hemostasis and vascular biology
234. A role for the alphavbeta3 integrin in the transmigration of monocytes
235. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells
236. Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin
237. ECM and cell surface proteolysis: Regulating cellular ecology
238. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
239. Alpha5beta1 integrin expression and luminal edge fibronectin matrix assembly by smooth muscle cells after arterial injury
240. Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoprosis
241. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits
242. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit
243. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits
244. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation
245. Prevention of restenosis by gene therapy
246. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery
247. Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty
248. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
249. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo
250. Effects of active and negative mutants of ras on rat arterial neointima formation
251. Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy
252. Gene therapy for coronary restenosis: A promising strategy for the new millennium?